Thomas P Schmidt1,2, David L Pennington1,2,3, Stephanie L Cardoos2,3, Timothy C Durazzo4,5, Dieter J Meyerhoff1,2,6. 1. a Department of Radiology , Northern California Institute for Research and Education , San Francisco , CA , USA. 2. b Department of Radiology , San Francisco Veterans Affairs Medical Center , San Francisco , CA , USA. 3. c Department of Psychiatry , University of California , San Francisco , CA , USA. 4. d Department of Psychiatry and Behavioral Sciences , Stanford University , Stanford , CA , USA. 5. e Department of Psychiatry , Veterans Affairs Palo Alto Health Care System , Palo Alto , CA , USA. 6. f Department of Radiology and Biomedical Imaging , University of California , San Francisco , CA , USA.
Abstract
INTRODUCTION: Intact neurocognition and early cognitive recovery during abstinence are important for substance use treatment outcome. Yet, little is known about them in the largest group of treatment seekers today, individuals with polysubstance use disorders (PSU). This study primarily contrasted PSU and individuals with an alcohol use disorder (AUD) on neurocognitive and inhibitory control measures and, secondarily, measured changes during abstinence in PSU. METHOD: At one month of abstinence from all substances except tobacco, 36 PSU and 69 AUD completed neurocognitive assessments of executive function, general intelligence, auditory-verbal learning/memory, visuospatial learning/memory/skills, processing speed, working memory, fine motor skills, and cognitive efficiency. The groups were also assessed on inhibitory control measures of self-reported impulsivity, risk-taking, and decision-making. Seventeen PSU repeated the assessments after approximately four months of abstinence. All cross-sectional and longitudinal analyses included smoking status as a possible confound. RESULTS: At baseline, PSU performed significantly worse than AUD on auditory-verbal memory and on an inhibitory control measure of impulsivity. Polysubstance users showed trends to worse performance than AUD on general intelligence, auditory-verbal learning, and a decision-making task. Between one and four months of abstinence, PSU showed significant improvements on several neurocognitive and inhibitory control measures. CONCLUSIONS: Polysubstance users exhibit distinct differences in neurocognition and inhibitory control compared to AUD. Between one and four months of abstinence, neurocognition and inhibitory control improve in PSU. This neurocognitive recovery in some domains of abstinent PSU is influenced by smoking status. These results underscore the clinical value of select methods to augment neurocognitive recovery in PSU through appropriate interventions.
INTRODUCTION: Intact neurocognition and early cognitive recovery during abstinence are important for substance use treatment outcome. Yet, little is known about them in the largest group of treatment seekers today, individuals with polysubstance use disorders (PSU). This study primarily contrasted PSU and individuals with an alcohol use disorder (AUD) on neurocognitive and inhibitory control measures and, secondarily, measured changes during abstinence in PSU. METHOD: At one month of abstinence from all substances except tobacco, 36 PSU and 69 AUD completed neurocognitive assessments of executive function, general intelligence, auditory-verbal learning/memory, visuospatial learning/memory/skills, processing speed, working memory, fine motor skills, and cognitive efficiency. The groups were also assessed on inhibitory control measures of self-reported impulsivity, risk-taking, and decision-making. Seventeen PSU repeated the assessments after approximately four months of abstinence. All cross-sectional and longitudinal analyses included smoking status as a possible confound. RESULTS: At baseline, PSU performed significantly worse than AUD on auditory-verbal memory and on an inhibitory control measure of impulsivity. Polysubstance users showed trends to worse performance than AUD on general intelligence, auditory-verbal learning, and a decision-making task. Between one and four months of abstinence, PSU showed significant improvements on several neurocognitive and inhibitory control measures. CONCLUSIONS: Polysubstance users exhibit distinct differences in neurocognition and inhibitory control compared to AUD. Between one and four months of abstinence, neurocognition and inhibitory control improve in PSU. This neurocognitive recovery in some domains of abstinent PSU is influenced by smoking status. These results underscore the clinical value of select methods to augment neurocognitive recovery in PSU through appropriate interventions.
Entities:
Keywords:
Addiction; Cognition; Impulsivity; Longitudinal; Recovery; Substance use disorders
Authors: C W Lejuez; Jennifer P Read; Christopher W Kahler; Jerry B Richards; Susan E Ramsey; Gregory L Stuart; David R Strong; Richard A Brown Journal: J Exp Psychol Appl Date: 2002-06
Authors: Chris C Streeter; Devin B Terhune; Theodore H Whitfield; Staci Gruber; Ofra Sarid-Segal; Marisa M Silveri; Golfo Tzilos; Maryam Afshar; Elizabeth D Rouse; Hua Tian; Perry F Renshaw; Domenic A Ciraulo; Deborah A Yurgelun-Todd Journal: Neuropsychopharmacology Date: 2007-06-13 Impact factor: 7.853
Authors: Jodie Naim-Feil; Paul B Fitzgerald; John L Bradshaw; Dan I Lubman; Dianne Sheppard Journal: Arch Clin Neuropsychol Date: 2013-12-13 Impact factor: 2.813
Authors: Claire E Wilcox; Charlene J Dekonenko; Andrew R Mayer; Michael P Bogenschutz; Jessica A Turner Journal: Rev Neurosci Date: 2014 Impact factor: 4.353
Authors: R D Hurt; K M Eberman; I T Croghan; K P Offord; L J Davis; R M Morse; M A Palmen; B K Bruce Journal: Alcohol Clin Exp Res Date: 1994-08 Impact factor: 3.455
Authors: Claire E Wilcox; Joshua Clifford; Josef Ling; Andrew R Mayer; Rose Bigelow; Michael P Bogenschutz; J Scott Tonigan Journal: Brain Imaging Behav Date: 2020-04 Impact factor: 3.978
Authors: Rosemary Fama; Anne-Pascale Le Berre; Stephanie A Sassoon; Natalie M Zahr; Kilian M Pohl; Adolf Pfefferbaum; Edith V Sullivan Journal: Drug Alcohol Depend Date: 2021-09-20 Impact factor: 4.492
Authors: Kristen N Amico; Miranda E Arnold; Morgan S Dourron; Matthew G Solomon; Jesse R Schank Journal: Psychopharmacology (Berl) Date: 2022-08-16 Impact factor: 4.415